Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-174M | $-157M | -96.8% | - | 39.8% |
| 2024 | $0M | $-122M | $-125M | $-101M | -90.9% | - | 29.9% |
| 2023 | $0M | $-93M | $-96M | $-96M | -75.9% | -100.0% | 11.7% |
| 2022 | $8M | $-97M | $-86M | $-101M | -40.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 8.09 | 0 | 0 | 0 |
| Operating Revenue | - | 8.09 | 0 | 0 | 0 |
| Operating Expense | - | 107.37 | 104.32 | 129.73 | 179.21 |
| Research And Development | - | 78.42 | 76.56 | 96.43 | 140.32 |
| Selling General And Administration | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Total Expenses | - | 107.37 | 104.32 | 129.73 | 179.21 |
| Operating Income | - | -99.27 | -104.32 | -129.73 | -179.21 |
| Total Operating Income As Reported | - | -106.45 | -104.25 | -129.73 | -179.21 |
| EBITDA | - | -96.87 | -92.99 | -121.90 | -177.57 |
| Normalized EBITDA | - | -107.92 | -93.06 | -117.15 | -171.52 |
| EBIT | - | -99.27 | -95.58 | -124.36 | -179.21 |
| Interest Income | - | 2.62 | 7.58 | 9.47 | 10.11 |
| Interest Expense | - | - | 0.44 | 0.34 | - |
| Net Interest Income | - | 2.62 | 7.14 | 9.13 | 10.11 |
| Other Non Operating Income Expenses | - | -0.38 | 1.10 | 0.65 | 0.82 |
| Other Income Expense | - | 10.68 | 1.16 | -4.10 | -5.23 |
| Interest Income Non Operating | - | 2.62 | 7.58 | 9.47 | 10.11 |
| Interest Expense Non Operating | - | - | 0.44 | 0.34 | - |
| Net Non Operating Interest Income Expense | - | 2.62 | 7.14 | 9.13 | 10.11 |
| Pretax Income | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income From Continuing And Discontinued Operation | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income From Continuing Operation Net Minority Interest | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Common Stockholders | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Including Noncontrolling Interests | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Normalized Income | - | -97.04 | -96.08 | -119.95 | -168.28 |
| Diluted NI Availto Com Stockholders | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Basic Average Shares | 7.12 | 8.51 | 19.88 | 40.82 | - |
| Diluted Average Shares | 7.12 | 8.51 | 19.88 | 40.82 | - |
| Reconciled Depreciation | - | 2.41 | 2.58 | 2.46 | 1.64 |
| Total Unusual Items | - | 11.06 | 0.06 | -4.75 | -6.05 |
| Total Unusual Items Excluding Goodwill | - | 11.06 | 0.06 | -4.75 | -6.05 |
| Special Income Charges | 0 | 11.06 | 0.06 | 0 | - |
| Restructuring And Mergern Acquisition | 0 | -11.06 | -0.06 | 0 | - |
| Gain On Sale Of Security | - | - | - | -4.75 | -6.05 |
| General And Administrative Expense | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Other Gand A | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Total Other Finance Cost | -0.06 | -2.62 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Solid Biosciences Inc.this co. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 |
| - |
| - |
| - |
| - |
| 8.91 |
| -14.9% |
| -46.77 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Peer Median | - | -12.07 | 3.02 | -24.2% | -6.95 | |
Historically, Dec has averaged the highest return (+14.4%); Apr the lowest (-18.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +14.5%Positive MonthJan 2026: +14.54% | -3.9%Negative MonthFeb 2026: -3.87% | +15.9%Positive MonthMar 2026: +15.94% | +0.8%Neutral MonthApr 2026: +0.83% | +1.1%Neutral MonthMay 2026: +1.10% | +36.1%Positive MonthJun 2026: +36.10% | -19.3%Negative MonthJul 2026: -19.32% | +20.8%*Positive MonthAug 2026: +20.84% | — | — | — | — |
| 2025 | -20.5%Negative MonthJan 2025: -20.50% | +75.8%Positive MonthFeb 2025: +75.79% | -33.8%Negative MonthMar 2025: -33.81% | -10.5%Negative MonthApr 2025: -10.54% | -3.0%Negative MonthMay 2025: -3.02% | +51.7%Positive MonthJun 2025: +51.71% | +40.5%Positive MonthJul 2025: +40.45% | -19.9%Negative MonthAug 2025: -19.88% | +12.6%Positive MonthSep 2025: +12.59% | -12.6%Negative MonthOct 2025: -12.64% | +0.7%Neutral MonthNov 2025: +0.74% | +3.9%Positive MonthDec 2025: +3.87% |
| 2024 | +12.2%Positive MonthJan 2024: +12.21% | +36.3%Positive MonthFeb 2024: +36.28% | +41.9%Positive MonthMar 2024: +41.85% | -33.4%Negative MonthApr 2024: -33.41% | -6.9%Negative MonthMay 2024: -6.88% | -31.4%Negative MonthJun 2024: -31.36% | +57.3%Positive MonthJul 2024: +57.32% | +0.1%Neutral MonthAug 2024: +0.11% | -21.9%Negative MonthSep 2024: -21.95% | -20.8%Negative MonthOct 2024: -20.80% | +3.3%Positive MonthNov 2024: +3.26% | -29.8%Negative MonthDec 2024: -29.82% |
| 2023 | +40.9%Positive MonthJan 2023: +40.89% | -25.9%Negative MonthFeb 2023: -25.86% | -15.7%Negative MonthMar 2023: -15.66% | +3.0%Positive MonthApr 2023: +2.95% | +26.6%Positive MonthMay 2023: +26.64% | -15.2%Negative MonthJun 2023: -15.21% | -17.7%Negative MonthJul 2023: -17.75% | -16.2%Negative MonthAug 2023: -16.24% | -30.2%Negative MonthSep 2023: -30.19% | -11.5%Negative MonthOct 2023: -11.51% | +26.5%Positive MonthNov 2023: +26.46% | +117.7%Positive MonthDec 2023: +117.73% |
| 2022 | -30.3%Negative MonthJan 2022: -30.29% | -33.2%Negative MonthFeb 2022: -33.20% | +47.2%Positive MonthMar 2022: +47.24% | -53.3%Negative MonthApr 2022: -53.33% | +1.8%Neutral MonthMay 2022: +1.79% | +8.1%Positive MonthJun 2022: +8.07% | +9.6%Positive MonthJul 2022: +9.58% | -5.2%Negative MonthAug 2022: -5.19% | -27.0%Negative MonthSep 2022: -27.03% | -8.5%Negative MonthOct 2022: -8.49% | +4.5%Positive MonthNov 2022: +4.52% | -19.7%Negative MonthDec 2022: -19.70% |
| 2021 | — | — | — | — | -25.3%Negative MonthMay 2021: -25.34% | -3.7%Negative MonthJun 2021: -3.68% | -23.8%Negative MonthJul 2021: -23.77% | -2.9%Negative MonthAug 2021: -2.87% | -11.8%Negative MonthSep 2021: -11.81% | -15.1%Negative MonthOct 2021: -15.06% | -13.8%Negative MonthNov 2021: -13.79% | +0.0%Neutral MonthDec 2021: +0.00% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
